The panel did indicate that the drug might have a place in a restricted population, though more data might be necessary.

FORBES: A Biotech's Big Comeback

Braunwald's panel recommended that use of Natrecor be limited to a more restricted population than that for which the drug is approved.

FORBES: Bitter Pill For J&J On Heart Drug

Pricing information was not immediately available, but given the restricted use and small population of patients who might use the drug, the price is likely to be high.

FORBES: AstraZeneca's Victory Highlights Difficulty Of Cancer Drug Development